Tradewell et al. showed that while AdOx treatment or PRMT1 knockdown at least 48 h prior to the transfection of ALS-FUS leads to diminished cytoplasmic ALS-FUS, concurrent PRMT1 knockdown alongside the transfection of ALS-FUS leads to an increase in cytoplasmic ALS-FUS [72]. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.